Seven Bridges Advisors LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Seven Bridges Advisors LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,250 shares of the biopharmaceutical company’s stock after buying an additional 151 shares during the period. Seven Bridges Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $614,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. raised its position in Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock valued at $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Wellington Management Group LLP raised its position in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock valued at $2,377,590,000 after buying an additional 446,850 shares during the last quarter. Vanguard Group Inc. raised its position in Regeneron Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 5,121,496 shares of the biopharmaceutical company’s stock valued at $1,984,630,000 after buying an additional 199,975 shares during the last quarter. State Street Corp raised its position in Regeneron Pharmaceuticals by 4.3% in the first quarter. State Street Corp now owns 3,380,151 shares of the biopharmaceutical company’s stock valued at $1,309,861,000 after buying an additional 139,602 shares during the last quarter. Finally, Artisan Partners Limited Partnership raised its position in Regeneron Pharmaceuticals by 2.2% in the first quarter. Artisan Partners Limited Partnership now owns 1,933,228 shares of the biopharmaceutical company’s stock valued at $749,145,000 after buying an additional 41,630 shares during the last quarter. Hedge funds and other institutional investors own 66.70% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 470.10 on Tuesday. The firm has a market cap of $49.63 billion, a PE ratio of 56.91 and a beta of 1.66. The company’s 50-day moving average price is $499.60 and its 200 day moving average price is $421.63. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. The business had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.82 EPS. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.83 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Seven Bridges Advisors LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.themarketsdaily.com/2017/08/08/seven-bridges-advisors-llc-boosts-stake-in-regeneron-pharmaceuticals-inc-nasdaqregn.html.

Several equities analysts have recently issued reports on REGN shares. Sanford C. Bernstein restated an “outperform” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, May 25th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $557.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 1st. Leerink Swann reiterated an “outperform” rating and issued a $493.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, June 13th. BMO Capital Markets reiterated a “hold” rating and issued a $421.00 price objective (up from $412.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, May 5th. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $450.00 price objective (up from $400.00) on shares of Regeneron Pharmaceuticals in a research report on Saturday, July 22nd. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $477.91.

In other news, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total value of $1,208,060.98. Following the completion of the transaction, the senior vice president now owns 9,193 shares of the company’s stock, valued at approximately $4,894,537.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Neil Stahl sold 8,306 shares of the stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the transaction, the executive vice president now directly owns 43,950 shares of the company’s stock, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. Insiders have sold a total of 59,396 shares of company stock valued at $28,484,734 in the last ninety days. 10.40% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply